[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama
Yasuo
Y
Pharmacology Research Laboratories II, Takeda Chemical Industries, Ltd.
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007333:Insulin Resistance; D008024:Ligands; D050356:Lipid Metabolism; D009765:Obesity; D000077205:Pioglitazone; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000502:physiology; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000819:agonists / Q000502:physiology
D007004:Hypoglycemic Agents; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; C089946:2,4-thiazolidinedione; D000077205:Pioglitazone